Showing papers by "Richard D. Carvajal published in 2006"
TL;DR: The multiple functions of Aurora kinase in the regulation of mitosis and the mitotic checkpoint are reviewed, the role of abnormal Aurora kinases activity in the development of cancer, the putative mechanisms of AuroraKinase inhibition and its antitumor effects, the developed of the first generation of Aurorakinase inhibitors, and prospects for the future of Aurora Kinase inhibition in the treatment of cancer.
Abstract: The Aurora kinase family is a collection of highly related serine/threonine kinases that functions as a key regulator of mitosis. In mammalian cells, Aurora has evolved into three related kinases known as Aurora-A, Aurora-B, and Aurora-C. These kinases are overexpressed in a number of human cancers, and transfection studies have established Aurora-A as a bone fide oncogene. Because Aurora overexpression is associated with malignancy, these kinases have been targeted for cancer therapy. This article reviews the multiple functions of Aurora kinase in the regulation of mitosis and the mitotic checkpoint, the role of abnormal Aurora kinase activity in the development of cancer, the putative mechanisms of Aurora kinase inhibition and its antitumor effects, the development of the first generation of Aurora kinase inhibitors, and prospects for the future of Aurora kinase inhibition in the treatment of cancer.
269 citations
TL;DR: Safingol (L-threo-dihydrosphingosine) has been re-identified as an inhibitor of sphingosinesine kinase (SK).
Abstract: 13044Background: Safingol (L-threo-dihydrosphingosine), originally identified as a competitive inhibitor of protein kinase C, has been re-identified as an inhibitor of sphingosine kinase (SK). Inhi...
9 citations
TL;DR: CPT followed by F is an ineffective therapy for HCC, and the wild type p53 of the patient with SD maybe a predictor of response in HCC where p53 mutations are common.
Abstract: 4148 Background: F is a CDK inhibitor which potentiates CPT- induced apoptosis. In a phase I trial of CPT 100mg/m2 followed 7 hours later by F given over 1 hour weekly for 4 out of 6 weeks (Shah, C...
8 citations
TL;DR: The abstracts are only available online, free of charge, under www.karger.com/doi/10.1159/000328511.
4 citations
TL;DR: The combination of flavopiridol and modified FOLFOX6 can be given safely without a significant increase in toxicity, with promising activity noted for colorectal cancers even with prior oxaliplatin chemotherapy.
Abstract: 13515 Background: Flavopiridol, a potent cyclin-dependent kinase inhibitor, enhances oxaliplatin-induced apoptosis in HCT116 colon cancer cells in vitro, especially with concurrent therapy. Signifi...
1 citations